Helus psychedelic depression drug succeeds in trial amid safety scrutiny
HELP•Helus Pharma said its experimental drug HLP003 significantly improved depression symptoms in a late-stage trial, but its US-listed shares fell more than 15% as investors focused on safety concerns, including a suicide attempt reported in the study.
1. Trial results
In a 222-patient study, HLP003 patients improved by 19.5 points on a standard depression scale after six weeks, compared with 11.9 points for placebo. Helus said the benefit appeared by day two and remained durable through 12 weeks. By week six, 50.9% of patients taking HLP003 achieved clinical remission, versus 18.2% on placebo; 56.3% had symptoms cut by at least half.
2. Safety concerns
Helus reported three treatment-related serious adverse events among patients receiving HLP003, including a suicide attempt by a patient who had not responded to treatment. The attempt occurred 55 days after the patient received a second dose. The patient was hospitalized two days after overdosing on a background antidepressant medication and was later discharged. Chief Medical Officer Amir Inamdar said the company’s assessment did not identify a suicidality signal.
3. Next study
Executives said Helus remains on track for a potential US regulatory filing in 2028, following data from a second study expected in late 2027. Jefferies analysts said HLP003’s efficacy exceeded investor expectations and described the week-six remission and response rates as meaningful.




